65. Primary immunodeficiency Clinical trials / Disease details

Clinical trials : 500 / Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217

9 trials found

diseases per page:

Showing 1 to 9 of 9 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03033745 (ClinicalTrials.gov)	February 1, 2017	23/1/2017	Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary ...	An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameter ...	Primary Immunodeficiency	Drug: IgPro20	CSL Behring	NULL	Completed	2 Years	N/A	All	49	Phase 4	United States;Canada
2	NCT01354587 (ClinicalTrials.gov)	October 2010	18/3/2011	Evaluation of Efficacy and Tolerability of Hizentra®	Evaluation of Efficacy and Tolerability of Hizentra®in Subjects Transitioning From Vivaglobin® (16% ...	Primary Immunodeficiency Disorders	Drug: Hizentra	University of South Florida	NULL	Recruiting	1 Year	75 Years	Both	50	N/A	United States
3	EUCTR2008-000830-30-GB (EUCTR)	10/12/2008	20/01/2009	Extension study designed to test the long-term safety and effectiveness of Immunoglobulin Subcutaneo ...	A Multicenter Extension Study of the Efficacy, Tolerability, and Safety of Immune Globulin Subcutane ...	PID (Primary Immune Deficiency) MedDRA version: 13.1;Level: PT;Classification code 10064859;Term: Pr ...	Product Name: Hizentra® Product Code: IgPro20 INN or Proposed INN: Human Normal Immunoglobulin	CSL Behring AG	NULL	Not Recruiting			Female: yes Male: yes	40	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	France;Spain;Poland;Romania;Germany;Switzerland;United Kingdom;Sweden
4	EUCTR2014-003605-15-Outside-EU/EEA (EUCTR)		26/02/2015	Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID) ...	A Multicenter Extension Study of the Efficacy, Tolerability, and Safety of Immune Globulin Subcutane ...	Primary Immune Deficiency (PID) MedDRA version: 17.1;Level: PT;Classification code 10064859;Term: Pr ...	Trade Name: Hizentra® INN or Proposed INN: Human Normal Immunoglobulin Other descriptive name: HUMAN N ...	CSL Behring AG	NULL	NA			Female: yes Male: yes	21		United States
5	EUCTR2014-003609-14-Outside-EU/EEA (EUCTR)		05/01/2015	Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan ...	A Multicenter Follow-up Study of Long-term Safety, Tolerability, and Efficacy of Immune Globulin Sub ...	Primary Immune Deficiency;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Hizentra® INN or Proposed INN: Human Normal Immunoglobulin Other descriptive name: HUMAN N ...	CSL Behring	NULL	NA			Female: yes Male: yes	23		Japan
6	EUCTR2014-003409-13-Outside-EU/EEA (EUCTR)		05/01/2015	Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects ...	A Multicenter Study of Long-Term Clinical Outcomes of Immune Globulin Subcutaneous (Human) (SCIG) Ig ...	Primary Immune Deficiency;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Hizentra® INN or Proposed INN: Human Normal Immunoglobulin Other descriptive name: Human N ...	CSL Behring	NULL	NA			Female: yes Male: yes	22		Japan
7	EUCTR2014-003607-30-Outside-EU/EEA (EUCTR)		26/02/2015	Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy	A Phase III Open-Label, Prospective, Multicenter Study of the Efficacy, Tolerability, Safety, and Ph ...	Primary Immune Deficiency MedDRA version: 17.1;Level: PT;Classification code 10064859;Term: Primary ...	Trade Name: Hizentra® Product Name: IgPro20 Product Code: IgPro20 INN or Proposed INN: Human Normal Imm ...	CSL Behring AG	NULL	NA			Female: yes Male: yes	49	Phase 3	United States
8	EUCTR2014-003608-61-Outside-EU/EEA (EUCTR)		05/01/2015	Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)	A Multicenter Study of Efficacy, Safety, Tolerability, and Pharmacokinetics of Immune Globulin Subcu ...	Primary Immune Deficiency;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Hizentra® INN or Proposed INN: Human Normal Immunoglobulin Other descriptive name: HUMAN N ...	CSL Behring	NULL	NA			Female: yes Male: yes	25		Japan
9	EUCTR2016-003799-33-Outside-EU/EEA (EUCTR)		30/01/2017	Safety and tolerability of higher infusion parameters of IgPro20 (Hizentra) in subjects with primary ...	An open-label multicenter study to evaluate the safety and tolerability of higher infusion parameter ...	Primary immunodeficiency MedDRA version: 19.1;Level: PT;Classification code 10064859;Term: Primary i ...	Trade Name: Hizentra Product Name: Hizentra; human normal immunoglobulin (subcutaneous) Product Code: I ...	CSL Behring LLC	NULL	NA			Female: yes Male: yes	51	Phase 4	United States;Canada

First Previous1Next Last